Predictive value of p53 and 14-3-3σ for the effect of chemoradiation therapy on esophageal squamous cell carcinoma

Journal of Surgical Oncology

Volumn 91, Issue 1, 2005, Pages 84-89

  Okumura, Hiroshi ^a   Natsugoe, Shoji ^a   Matsumoto, Masataka ^a   Yokomakura, Naoya ^a   Uchikado, Yasuto ^a   Takatori, Hiroyuki ^a   Ishigami, Sumiya ^a   Takao, Sonshin ^a   Aikou, Takashi ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

14 3 3 ; Chemoradiation; Esophageal cancer; p53

Indexed keywords

CISPLATIN; FLUOROURACIL; PROTEIN 14 3 3; PROTEIN 14 3 3 SIGMA; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE; DNA DAMAGE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE EXPRESSION; GENOTOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; EXONUCLEASES; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 22044431584     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20279     Document Type: Article

References (17)

1. Baba M, Aikou T, Yoshinaka H, et al.: Long-term results of subtotal esophagectomy with three-field lymphadenectomy for carcinoma of the thoracic esophagus. Ann Surg 1994;219:310-316.
2. Naunheim KS, Petruska P, Roy TS, et al.: Preoperative chemotherapy and radiotherapy for esophageal carcinoma. J Thorac Cardiovasc Surg 1992;103:887-893.
3. John MJ, Flam MS, Mowry PA, et al.: Radiotherapy alone and chemoradiation for nonmetastatic esophageal carcinoma. A critical review of chemoradiation. Cancer 1989;632:397-403.
4. Nakano S, Baba M, Natsugoe S, et al.: The role of neoadjuvant radiochemotherapy using low-dose fraction cisplatin and 5-fluorouracil in patients with carcinoma of the esophagus. Jpn J Thorac Cardiovasc Surg 2001;49:11-16.
5. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-1462.
6. Chan TA, Hermeking H, Lengauer C, et al.: 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 1999;401:616-620.
7. Lowe SW, Bodis S, McClatchey A, et al.: p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-810.
8. Kishi K, Doki Y, Miyata H, et al.: Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer. Br J Surg 2002;89:597-603.
9. Sarbia M, Stahl M, Fink U, et al.: Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities. Clin Cancer Res 1998;4: 2991-2997.
10. Sobin LH, Wittwkind CH: TNM classification of malignant tumors, internationale union against cancer, 5th edn. New York: John Wiley & Sons; 1997.
11. Japanese Society for Esophageal Diseases: Guidelines for clinical and pathologic studies on carcinoma of the esophagus, 9th edn. Tokyo: Kanehara; 1999.
12. Natsugoe S, Nakashima S, Matsumoto M, et al: Expression of p21WAF1/Cip1 in the p53-dependent pathway is related to prognosis in patients with advanced esophageal carcinoma. Clin Cancer Res 1999;5:2445-2449.
13. Hollstein M, Sidransky D, Vogelstein B, et al.: p53 mutations in human cancers. Science 1991;253:49-53.
14. Aurelio ON, Kong XT, Gupta S, et al.: p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines. Mol Cell Biol 2000;20:770-778.
15. Wang Y, Li J, Booher RN, et al.: Radiosensitization of p53 mutant cells by PD0166285. a novel G2 checkpoint abrogator. Cancer Res 2001;61:8211-8217.
16. Tanaka H, Arakawa H, Yamaguchi T, et al: A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 2000;404:42-49.
17. Kaneuchi M, Sasaki M, Tanaka Y, et al.: Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer. Biochem Biophys Res Commun 2004;316:1156-1162.